Search results for "anti-obesity drug"

showing 3 items of 3 documents

Novel anti-obesity drugs and plasma lipids

2014

Obesity is a health problem of global, epidemic proportions and a major risk factor for chronic diseases resulting in accelerated morbidity and mortality. Dyslipidemia with a predominance of small dense LDL, impaired functionality of HDL particles, and increased serum levels of remnant particles due to impaired clearance of triglyceriderich lipoproteins significantly heightens cardiovascular events in obese subjects. Pharmacotherapy in combination with lifestyle modification is the primary approach to reduce obesity-related cardiovascular risk. Although there are several potential anti-obesity drugs, orlistat is the only agent that remains available in the market. Lorcaserin and Qsymia ® , …

business.industryEndocrinology Diabetes and MetabolismTherapeutic effectPharmacologymedicine.diseaseObesityanti-obesity drugs contrave dyslipidemia lorcaserin low-density lipoprotein obesity Qsymia® triglycerideLorcaserinOrlistatPharmacotherapymedicineRisk factorCardiology and Cardiovascular MedicineAdverse effectbusinessDyslipidemiamedicine.drug
researchProduct

Lipoprotein Subfractions in Metabolic Syndrome and Obesity: Clinical Significance and Therapeutic Approaches

2013

Small, dense low density lipoprotein (sdLDL) represents an emerging cardiovascular risk factor, since these particles can be associated with cardiovascular disease (CVD) independently of established risk factors, including plasma lipids. Obese subjects frequently have atherogenic dyslipidaemia, including elevated sdLDL levels, in addition to elevated triglycerides (TG), very low density lipoprotein (VLDL) and apolipoprotein-B, as well as decreased high density lipoprotein cholesterol (HDL-C) levels. Obesity-related co-morbidities, such as metabolic syndrome (MetS) are also characterized by dyslipidaemia. Therefore, agents that favourably modulate LDL subclasses may be of clinical value in t…

lipoproteinsobesity treatmentobesitysmall dense low density lipoproteinlipid-lowering drugsanti-obesity drugslipids (amino acids peptides and proteins)metabolic syndrome
researchProduct

Lipoprotein Subfractions in Metabolic Syndrome and Obesity: Clinical Significance and Therapeutic Approaches

2013

Small, dense low density lipoprotein (sdLDL) represents an emerging cardiovascular risk factor, since these particles can be associated with cardiovascular disease (CVD) independently of established risk factors, including plasma lipids. Obese subjects frequently have atherogenic dyslipidaemia, including elevated sdLDL levels, in addition to elevated triglycerides (TG), very low density lipoprotein (VLDL) and apolipoprotein-B, as well as decreased high density lipoprotein cholesterol (HDL-C) levels. Obesity-related co-morbidities, such as metabolic syndrome (MetS) are also characterized by dyslipidaemia. Therefore, agents that favourably modulate LDL subclasses may be of clinical value in t…

obesitymedicine.medical_specialtyVery low-density lipoproteinLipoproteinslipid-lowering drugsanti-obesity drugslcsh:TX341-641030209 endocrinology & metabolismReview030204 cardiovascular system & hematologyOverweight03 medical and health scienceschemistry.chemical_compound0302 clinical medicineHigh-density lipoproteinInternal medicineHumansMedicineRisk factorDyslipidemiasMetabolic Syndromeobesity treatmentNutrition and Dieteticssmall dense low density lipoproteinbusiness.industryCholesterollipoproteinmedicine.disease3. Good healthEndocrinologychemistryCardiovascular DiseasesLow-density lipoproteinlipids (amino acids peptides and proteins)Metabolic syndromemedicine.symptombusinesslcsh:Nutrition. Foods and food supplyanti-obesity drugFood ScienceLipoproteinNutrients
researchProduct